VA-INTELSAT
26.6.2024 17:01:35 CEST | Business Wire | Press release
Intelsat, operator of the world’s largest integrated satellite and terrestrial network, signed a contract for a Starfish Otter servicing vehicle to provide life extension services to an Intelsat geostationary satellite, beginning in 2026. This landmark agreement reinforces Intelsat’s commitment to utilizing satellite servicing technologies to maximize the value its satellites can provide to customers and will mark Starfish’s first mission to provide services to a commercial satellite operator with Otter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626723807/en/
Starting in 2026, Starfish Space’s Otter will dock with a retired Intelsat satellite during a checkout campaign before maneuvering to dock with and service one of Intelsat’s operational satellites. (Courtesy: Starfish Space).
“For six decades, Intelsat has shown commitment to innovation and leveraging new technologies from throughout the industry,” said Jean-Luc Froeliger, Intelsat's Senior Vice President of Space Systems. “By engaging with emerging ventures, we create unique value for Intelsat while fostering a dynamic and competitive environment that drives advancement in space systems. Starfish is the perfect example of this kind of progress, and we look forward to utilizing the services provided by their Otter satellite to maximize the value the world’s largest geostationary satellite fleet can deliver for our customers.”
Intelsat has been a pioneer of extending satellite missions, signing its first agreement for satellite life extension in 2016, and procuring multiple additional life extension missions in recent years. The contract between Intelsat and Starfish represents a significant step for both companies, expanding the market for satellite servicing, and pushing the industry towards a new paradigm for satellite operations. With its Otter spacecraft, Starfish Space utilizes a small satellite architecture and breakthrough hardware and software technologies to provide rapid, flexible, and cost-effective on-orbit servicing missions for satellites.
Starfish will begin its first servicing mission for Intelsat in 2026. Initially, Otter will dock with and maneuver a retired Intelsat satellite in geostationary graveyard orbit. Following this initial operation, Otter will proceed to dock with and provide life extension service to an operational Intelsat satellite, using its onboard propulsion system to keep the client satellite in operational orbit for additional years of life.
“Starfish Space is delighted to be supporting Intelsat with services provided by Otter,” said Dr. Trevor Bennett, Co-Founder of Starfish Space. “They are an incredible team at the forefront of the industry and the Otter will help them deliver even more to their customers. We're also excited that this will be the first of many Otters that will make on-orbit servicing a standard part of satellite operations.”
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
About Starfish Space
Starfish Space is developing the Otter servicing vehicle to extend the lives of satellites in geostationary orbit and dispose of space debris in low-Earth orbit. Starfish has secured contracts for its first Otter missions with Intelsat and the U.S. Space Force, two of the largest global satellite operators. The company launched its Otter Pup demonstration mission in June 2023 and is now delivering on several satellite RPOD missions including its Otter mission for Intelsat. For more information, please visit starfishspace.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626723807/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
